home > news > detailed info

BioIVT Appoints Alan Findlater as Chief Commercial Officer


BioIVT is expanding its global commercial capabilities in response to growing demand for its biospecimens and specialized research services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has appointed Alan Findlater to the newly-created role of chief commercial officer. In his new position, Mr. Findlater will be responsible for all of BioIVT’s commercial activities, including global sales, marketing and customer service.

“Alan is a visionary leader with the requisite knowledge and experience to help guide BioIVT on its rapid growth trajectory as we continue to be the trusted leader for biological products and services,” said BioIVT Chief Executive Officer Jeffrey Gatz. “Alan has successfully built and led global sales, marketing and commercial operation teams at several major organizations, and his strong services sales background aligns closely with our recent acquisitions. Equally important, he shares BioIVT’s commitment to excellent customer service and product quality. I am delighted to welcome Alan to our executive team.”

BioIVT has acquired five companies – Asterand Bioscience, Qualyst Transporter Solutions, Optivia Biotechnology, Ascendance Biotechnology, and Clinical Trials Laboratory Services – since August 2017.

“BioIVT is at an exciting inflection point in its development due to a surge in demand for its research models and services. For example, the healthcare industry’s increasing focus on personalized medicine is resulting in a corresponding increase in patient screening and specimen inclusion/exclusion criteria for preclinical development. This is creating a need for more specialized biospecimens, with comprehensive clinical data, to test new drug candidates for safety and efficacy,” said Mr. Findlater.

Mr. Findlater has more than 33 years’ experience in the pharmaceutical, medical device, and R&D services sectors. He was chief commercial officer at WIL Research Laboratories for more than five years before it was acquired by Charles River Laboratories in April 2016.

Mr. Findlater was appointed Charles Rivers’ executive director, global business development, safety assessment, discovery and research models post-acquisition and led the commercial integration of both WIL Research Laboratories and Agilux discovery services.

Prior to that, Mr. Findlater held several senior global management positions at Covance Laboratories Inc., culminating in global vice president of sales and client services Early Pharmaceutical Development.

Mr. Findlater has a bachelor’s degree in chemistry from the University of Strathclyde and a master’s degree in business administration from the University of Warwick Business School, UK.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit or follow the company on Twitter @BioIVT.
phone +1 516 483 1196
email PO Box 770, Hicksville, NY, 11802-0770
Print this page
Send to a friend
News and Press Releases

Aptar Pharma Co Organizer and Diamond Sponsor of RDD Europe 2019 Conference in Estoril Portugal

Crystal Lake, Illinois, March 21, 2019 Aptar Pharma, the leader in respiratory drug delivery systems, is proud to announce its coorganization and diamond sponsorship of the Respiratory Drug Delivery (RDD®) Europe 2019 scientific conference, connecting pulmonary and nasal drug delivery experts from around the world in Estoril, Portugal from May 7-10, 2019.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices


An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

Industry Events

9th Annual Outsourcing in Clinical Trials Europe 2019

14-15 May 2019, Milan, Italy

Now in its 9th year, the Outsourcing in Clinical Trials Europe event is firmly established as the leading platform for the biopharmaceutical industry to collaborate to improve clinical trial partnerships, accelerate development timelines and leverage new technologies. Over 500 clinical professionals from biopharmaceutical and solution-provider companies attended the 2018 conference in Barcelona to develop new partnerships and find answers to their most pressing clinical trial challenges.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement